Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal. South Korean SBL will now also produce UCB’s anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB’s anti-tau candidate is currently in Phase I clinical studies.
UCB is a biopharmaceutical company, headquartered in Belgium, with over 90 years focusing on neurology and immunology.
“Our aim at UCB is to help people suffering from severe chronic diseases in areas of high unmet needs, and we need to work with organisations with proven track records to secure world-class manufacturing capabilities to bring our future drugs to patients,” said Scott Russell, Head of Partnerships & Alliances at UCB.
“This new agreement will also provide us the opportunity to showcase SBL’s newest facility, Plant 3, and demonstrate our proven track record of operational and regulatory success to enable UCB’s treatment of patients with this debilitating disease,” said Dr Tae Han Kim, President and CEO of Samsung BioLogics.
This will be the third product from UCB to be supplied by Samsung BioLogics under a master services agreement between the parties announced in July 2018. SBL and UCB previously signed two sub-agreements to manufacture UCB’s products currently in clinical development, for addressing the needs of patients affected by myasthenia gravis, psoriasis and psoriatic arthritis.
